不幸的是，卵巢癌仍然最常在晚期才被诊断出来，而且也是最致命的妇科癌症。另一个问题是接受治疗的患者疾病复发的风险很高。此外，卵巢癌在分子、组织学特征和突变方面非常多样化。许多患者还可能出现铂类耐药，导致对后续治疗反应不佳。为了改善卵巢癌患者的预后，期望改进现有的并实施新的、有前途的治疗方法。靶向治疗似乎非常有前途。目前，贝伐珠单抗（一种 VEGF 抑制剂）和奥拉帕尼（一种聚 ADP 核糖聚合酶抑制剂）疗法已获得批准。未来值得考虑的其他方法包括：叶酸受体α、免疫检查点或其他免疫治疗方法。为了改善卵巢癌的治疗，改善分子特征的确定以描述和了解哪组患者将从给定的治疗方法中受益最多也很重要。这一点很重要，因为接受卵巢癌治疗的患者群体越大，生存时间越长且不会复发的机会就越大。版权所有 © 2024 Satora、Kułak、Zaremba、Grunwald、Świechowska-Starek 和 Tarkowski。

Unfortunately, ovarian cancer is still diagnosed most often only in an advanced stage and is also the most lethal gynecological cancer. Another problem is the fact that treated patients have a high risk of disease recurrence. Moreover, ovarian cancer is very diverse in terms of molecular, histological features and mutations. Many patients may also develop platinum resistance, resulting in poor response to subsequent lines of treatment. To improve the prognosis of patients with ovarian cancer, it is expected to make better existing and implement new, promising treatment methods. Targeted therapies seem very promising. Currently, bevacizumab - a VEGF inhibitor and therapy with olaparib - a polyADP-ribose polymerase inhibitor are approved. Other methods worth considering in the future include: folate receptor α, immune checkpoints or other immunotherapy methods. To improve the treatment of ovarian cancer, it is also important to ameliorate the determination of molecular features to describe and understand which group of patients will benefit most from a given treatment method. This is important because a larger group of patients treated for ovarian cancer can have a greater chance of surviving longer without recurrence.Copyright © 2024 Satora, Kułak, Zaremba, Grunwald, Świechowska-Starek and Tarkowski.